Using nonpeptide, small molecule targeting, Radionetics Oncology is advancing a pipeline of drug candidates to treat a wide range of cancers by selectively binding to peptide receptors expressed on tumors. Their technology overcomes challenges faced by peptide and protein targeted radiotherapeutics, particularly in drug optimization and manufacturing. The company is also collaborating with Crinetics Pharmaceuticals to identify drug candidates for additional receptor targets.